Meeting
2022 ASCO Annual Meeting
Safety interim analysis (SIA) of atractib: A phase 2 trial of first-line (1L) atezolizumab (A) in combination with paclitaxel (P) and bevacizumab (B) in metastatic triple-negative breast cancer (mTNBC).
Authors
Maria Cortes
Hospital Ramon y Cajal, Madrid, Spain
Maria Cortes , Alfonso Cortés Salgado , Serafin Morales Murillo , Isabel Blancas , Patricia Cortez , Isabel Calvo Plaza , Nieves Diaz Fernandez , Alejandro Martinez-Bueno , Manuel Ruiz-Borrego , Salvador Blanch , Elisenda Llabres , Frederik Marmé , Peter Schmid , Valentina Guarneri , Joseph Gligorov , José Manuel Pérez-García , Miguel Sampayo-Cordero , Andrea Malfettone , Antonio Llombart Cussac , Javier Cortes
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Triple-Negative
Clinical Trial Registration Number
NCT04408118
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 1084)
DOI
10.1200/JCO.2022.40.16_suppl.1084
Abstract #
1084
Poster Bd #
462
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
FoRT 05-BEAT: A phase II randomized trial comparing atezolizumab versus atezolizumab + bevacizumab as first-line treatment in patients with PD-L1 high advanced/metastatic NSCLC.
First Author: Rita Migliorino
Poster
2019 ASCO Annual Meeting
Phase II COLET study: Atezolizumab (A) + cobimetinib (C) + paclitaxel (P)/nab-paclitaxel (nP) as first-line (1L) treatment (tx) for patients (pts) with locally advanced or metastatic triple-negative breast cancer (mTNBC).
First Author: Adam Brufsky
Poster
2016 ASCO Annual Meeting
IMpassion130: a Phase III randomized trial of atezolizumab with nab-paclitaxel for first-line treatment of patients with metastatic triple-negative breast cancer (mTNBC).
First Author: Leisha A. Emens
Poster
2023 ASCO Annual Meeting
The efficacy and safety of tislelizumab plus bevacizumab and chemotherapy as first line therapy in patients with persistent, recurrent, or metastatic cervical cancer: A multicenter, phase II study.
First Author: Jianqing Zhu